121 Bio Overview
- Founded
-
2013
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
121 Bio General Information
Description
Developer of a suite of innovative research tools designed for modification of proteins and cells and innovative cellular immunotherapies. The company's research tools will help drive fundamental new discoveries in protein structure/function and through systematic and deliberate modification of proteins, providing a platform for development of protein-based drugs with enhanced performance.
Contact Information
Primary Industry
Biotechnology
Other Industries
Other Healthcare
Primary Office
- 700 Main Street
- Cambridge, MA 02139
- United States
+1 (617) 000-0000
121 Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Out of Business | 01-May-2017 | Completed | Out of Business | |||
| 1. Early Stage VC (Series A) | 01-Jan-2014 | Completed | Startup |
121 Bio Executive Team (4)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Vanessa Winfield | Operations Manager | ||
| Gregg Beloff JD | Chief Financial Officer | ||
| Ramani Varanasi | Chief Business Officer |
121 Bio Board Members (4)
| Name | Representing | Role | Since |
|---|---|---|---|
| Hidde Ploegh Ph.D | Self | Co-Founder & Board Member | 000 0000 |